Thermo Fisher Scientific Inc (TMO) Position Cut by John G Ullman & Associates Inc.
John G Ullman & Associates Inc. reduced its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 0.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,233 shares of the medical research company’s stock after selling 100 shares during the period. John G Ullman & Associates Inc.’s holdings in Thermo Fisher Scientific were worth $4,577,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the stock. Proficio Capital Partners LLC increased its stake in Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after buying an additional 253 shares during the period. Cribstone Capital Management LLC increased its stake in Thermo Fisher Scientific by 8.7% in the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock worth $109,000 after buying an additional 50 shares during the period. Independent Portfolio Consultants Inc. increased its stake in Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock worth $112,000 after buying an additional 2 shares during the period. Sharkey Howes & Javer increased its stake in Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after buying an additional 7 shares during the period. Finally, CWM LLC increased its stake in Thermo Fisher Scientific by 17.0% in the second quarter. CWM LLC now owns 710 shares of the medical research company’s stock worth $124,000 after buying an additional 103 shares during the period. 83.52% of the stock is owned by institutional investors.
Thermo Fisher Scientific Inc (NYSE:TMO) opened at 182.95 on Thursday. The firm has a market cap of $71.37 billion, a P/E ratio of 31.87 and a beta of 1.06. The company has a 50-day moving average of $176.80 and a 200 day moving average of $167.41. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $183.32.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. During the same period in the previous year, the firm earned $2.03 earnings per share. The company’s revenue was up 10.2% on a year-over-year basis. On average, equities analysts predict that Thermo Fisher Scientific Inc will post $9.33 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be paid a $0.15 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.33%. Thermo Fisher Scientific’s payout ratio is 10.45%.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/31/thermo-fisher-scientific-inc-tmo-position-cut-by-john-g-ullman-associates-inc.html.
Several research analysts have recently issued reports on TMO shares. Cleveland Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Bank of America Corporation lifted their price target on Thermo Fisher Scientific from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, May 9th. Argus reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. BidaskClub downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 27th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $175.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, May 17th. One equities research analyst has rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average target price of $188.56.
In other news, Director Jim P. Manzi sold 11,318 shares of the business’s stock in a transaction dated Friday, August 18th. The stock was sold at an average price of $172.94, for a total value of $1,957,334.92. Following the sale, the director now directly owns 38,757 shares in the company, valued at $6,702,635.58. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Seth H. Hoogasian sold 4,140 shares of the business’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $177.80, for a total value of $736,092.00. Following the completion of the sale, the vice president now owns 25,518 shares in the company, valued at $4,537,100.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,958 shares of company stock valued at $3,309,277. Insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.